This is corroborated by several studies which have suggested a higher risk of TB development in the first months of TNF inhibitors therapy, a phenomenon attributable to reactivation of latent disease.[46,48–50] In addition, considering the disease-free survival time, there was a significantly higher likelihood of developing TB over the years in patients exposed to ADA than in those exposed to ETN, as well as a significantly higher likelihood of TB onset in the first year of exposure among CZP users in relation to all other TNF inhibitors agents. The gene discussed is ADA; the disease is tuberculosis.